Investors may first refer to the two articles I had shared on yesterday first:

Article #1: https://klse.i3investor.com/blogs/newsahring/2021-08-17-story-h1569773932-UAE_donates_1_million_doses_of_Covid_19_vaccine_to_Malaysia.jsp

Article #2: https://klse.i3investor.com/blogs/newsahring/2021-08-17-story-h1569773931-Philippines_approves_emergency_use_of_Hayat_Vax_vaccines.jsp

In both of the article, it was mentioned that the donation of vaccine and this Hayat-Vax vaccine. What exactly is this Hayat-Vax?

Hayat-Vax is a joint collaboration between Sinopharm CNBG and Abu Dhabi’s G42, and the UAE is likely to donate this vaccine to Malaysia. But who is the front runner in dealing in the Hayat-Vax vaccine, after the 1 million dosage is utilized?

Please refer to this article first appeared on NST dated 19^th July.

Article #3: https://www.nst.com.my/business/2021/07/709797/kanger-buy-50mil-sinopharm-covid-19-vaccine-uae-malaysian-sale

The short answer would be KANGER.

KANGER, via their subsidiary Kanger Medical International Sdn Bhd had planned to purchase five million vaccine doses from UAE for the delivery in Malaysia. Based on approximate 400,000 ~ doses administrated in Malaysia, the existing supply is likely to run out soon.

Hence our government needs additional vaccine supplies.

According to our sources, Hayat-Vax was already in the process of applying for the big question for investors – the NPRA, and it was very likely to be approved soon as our government accepted the donation of vaccines.

However, the price of KANGER had not moved an inch yet – indicating investors had not digested the latest articles yet.

Could this be our chance to profit from the rare vaccine orientated theme?!